A diverse scientific collaboration has developed vascularized 3-D bioprinted liver tissue constructs, providing more precise drug toxicity testing and possibly providing tailored testing samples using a patient’s own cells.
From the Journal: Biomicrofluidics
WASHINGTON, D.C., August 3, 2017 — Artificially constructed human tissues and organs have been developed with a number of different purposes in mind, from advanced robotics and novel materials to drug screening. The precision demanded by drug screening applications puts especially large demands on how accurately biomimetic constructs replicate tissue characteristics and behaviors involved in drug absorption.
A new advance, published this week in the journal Biomicrofluidics, from AIP Publishing, now offers the ability to construct vascularized tissue and mimic in vivo drug administration in 3-D bioprinted liver tissue. A truly international collaboration, with researchers affiliated with Chile, Italy, Saudi Arabia, Korea and the U.S., developed this relatively simple liver model to offer a more accurate system for drug toxicity testing.
“Most drug test models use a two-dimensional (2-D) monolayer cell tissue, or a 3-D tissue, but without this network,” said Su Ryon Shin, an instructor conducting research at the Harvard Medical School and one of the study’s authors. “Our bodies are actually composed of a 3-D construct with a vascular network, not composed of [just] single cells.”
The 3-D structure better mimics the architecture and functionality of complex human tissue compared to 2-D monolayers of cell models, due to their enhanced cell-cell interactions and improved cellular functions. These 3-D structures provide an improved tissue model and deliver more realistic drug responses than their 2-D counterparts. This new vascularized sample offers greater predictive ability for real toxicity levels the body would experience.
Printed with bio-ink that uses sacrificial microchannel scaffolding, the final endothelial cell-layered channel network allows observation of in vivo effects of drug absorption without having to actually do an in vivo study. Moreover, the technique can be adapted to different cell types to likely offer patient-tailored testing of drug toxicity.
“We are using human cells, and when we developed this technique we [did so in a way that let us] easily change the cell type, using maybe a patient’s primary cell or their endothelial cells and we can [potentially] create a human-specialized tissue model,” Shin said.
Although the construct is still a rather simplified version of actual liver tissue, this vascular model’s new level of complexity has already helped the team discover an important mechanism a monolayer construct could never reveal.
“Based on our finding, the endothelial layer delays the drug diffusion response, compared to without the endothelial layer,” Shin said. “They don’t change any drug diffusion constants, but they delay the permeability, so they delay the [response] as it takes time to pass through the endothelial layer.”
Shin in particular plans to focus future research on this diffusion step, and how it can be tuned to optimize drug absorption. More broadly, the group hopes that this is only an early step in developing more complex and faster bioprinted drug testing systems, such as multi-organ-on-a-chip devices and sample models for other organ and tissue systems. Cancer drug therapies, for example, require an understanding of the effects on various tissues outside of just the cancer tissue itself, and would benefit greatly from such a construct.
S. Massa, M.A. Sakr, J. Seo, P. Bandaru, A. Arneri, S. Bersini, E. Zare-Elanjegh, E. Jalilian, B.-H. Cha, S. Antona, A. Enrico, Y. Gao, S. Hassan, J.P.A. Cox, M.R. Dokmeci, Y.S. Zhang, A. Khademhosseini and S.R. Shin
Harvard Medical School, KTH Royal Institute of Technology, University of the Andes, IRCCS Istituto Ortopedico Galeazzi, Konkuk University, King Abdulaziz University